The results show that 35 patients (6.6%) are referred to rheumatology, nearly all rheumatic irAEs occur in the context of anti-PD-1/PD-L1 antibody treatments, and patients with rheumatic irAEs show a higher tumor response rate [64]. This evidence concerns the gene PDCD1 and neoplasm.